Home › NCT07226154

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

An Exosomal miRNA Based Predictive Model for Personalized Neoadjuvant Chemotherapy Selection in Pancreatic Ductal Adenocarcinoma

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
* Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
* Availability of pre-treatment plasma samples.
* Underwent curative-intent resection (R0 or R1).

Exclusion Criteria:

* Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
* Non-adenocarcinoma histology.
* Presence of synchronous or multiple primary malignancies.
* Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
* Presence of active inflammatory or autoimmune diseases.

About the study

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

What is being tested

• Small RNA sequencing (diagnostic test)
• PRECEPT assay (qRT-PCR validation) (diagnostic test)

Sponsor: City of Hope Medical Center · Participants: 200 · Started: Nov 15, 2024

Contact the study team

• Ajay Goel, PhD · Phone: 626-218-3452

Official record on ClinicalTrials.gov — NCT07226154

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.